Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Ovarian Neoplasms

Free Subscription Articles published in BMC Cancer Retrieve available abstracts of 128 articles: HTML format

Single Articles

September 2023
1. CHEN L, Tang Q, Zhang K, Huang Q, et al
   Altered expression of the L-arginine/nitric oxide pathway in ovarian cancer: metabolic biomarkers and biological implications.
   BMC Cancer. 2023;23:844.
   PubMed     Abstract available
   
   
   August 2023
2. O'BRIEN S, Butticello M, Thompson C, Wilson B, et al
   Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer.
   BMC Cancer. 2023;23:775.
   PubMed     Abstract available
   
   
   
3. OFVERHOLM A, Torngren T, Rosen A, Arver B, et al
   Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
   BMC Cancer. 2023;23:738.
   PubMed     Abstract available
   
   
   July 2023
4. CHITRANGI S, Vaity P, Jamdar A, Bhatt S, et al
   Patient-derived organoids for precision oncology: a platform to facilitate clinical decision making.
   BMC Cancer. 2023;23:689.
   PubMed     Abstract available
   
   
   
5. BATISTA MP, Roffe M, Romero I, Lopez-Guerrero JA, et al
   Genomic landscapes of ovarian clear cell carcinoma from latin countries reveal aberrations linked to survival and progression.
   BMC Cancer. 2023;23:613.
   PubMed     Abstract available
   
   
   
6. GEBHART P, Singer CF, Gschwantler-Kaulich D
   CA125 Levels in BRCA mutation carriers - a retrospective single center cohort study.
   BMC Cancer. 2023;23:610.
   PubMed     Abstract available
   
   
   
7. CHEN S, Lu H, Jiang S, Li M, et al
   An analysis of clinical characteristics and prognosis of endometrioid ovarian cancer based on the SEER database and two centers in China.
   BMC Cancer. 2023;23:608.
   PubMed     Abstract available
   
   
   June 2023
8. HALLSSON LR, Sroczynski G, Engel J, Siebert U, et al
   Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations.
   BMC Cancer. 2023;23:590.
   PubMed     Abstract available
   
   
   
9. LI X, Li X, Hu Y, Liu O, et al
   PSMD8 can serve as potential biomarker and therapeutic target of the PSMD family in ovarian cancer: based on bioinformatics analysis and in vitro validation.
   BMC Cancer. 2023;23:573.
   PubMed     Abstract available
   
   
   
10. MALEKI Z, Vali M, Nikbakht HA, Hassanipour S, et al
    Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:558.
    PubMed     Abstract available
    
    
    May 2023
11. DUAN C, Li K, Pan X, Wei Z, et al
    Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center.
    BMC Cancer. 2023;23:489.
    PubMed     Abstract available
    
    
    
12. FANALE D, Brando C, Corsini LR, Cutaia S, et al
    Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
    BMC Cancer. 2023;23:437.
    PubMed     Abstract available
    
    
    April 2023
13. MELKI R, Melloul M, Aissaoui S, El Harroudi T, et al
    Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.
    BMC Cancer. 2023;23:339.
    PubMed     Abstract available
    
    
    
14. LI J, Liang H, Xiao W, Wei P, et al
    Whole-exome mutational landscape and molecular marker study in mucinous and clear cell ovarian cancer cell lines 3AO and ES2.
    BMC Cancer. 2023;23:321.
    PubMed     Abstract available
    
    
    
15. REIJONEN M, Holopainen E, Arponen O, Kononen M, et al
    Neoadjuvant chemotherapy induces an elevation of tumour apparent diffusion coefficient values in patients with ovarian cancer.
    BMC Cancer. 2023;23:299.
    PubMed     Abstract available
    
    
    March 2023
16. LIU S, Feng S, Du F, Zhang K, et al
    Association of smoking, alcohol, and coffee consumption with the risk of ovarian cancer and prognosis: a mendelian randomization study.
    BMC Cancer. 2023;23:256.
    PubMed     Abstract available
    
    
    
17. BATES KM, Vathiotis I, MacNeil T, Ahmed FS, et al
    Spatial characterization and quantification of CD40 expression across cancer types.
    BMC Cancer. 2023;23:220.
    PubMed     Abstract available
    
    
    February 2023
18. LEKKA S, Psomiadou V, Panoskaltsis T, Tsouma E, et al
    CytoSaLPs score: a promising new tool for the detection and screening of extrauterine high grade serous carcinoma.
    BMC Cancer. 2023;23:157.
    PubMed     Abstract available
    
    
    January 2023
19. CHAI H, Pan C, Zhang M, Huo H, et al
    Histone methyltransferase SETD1A interacts with notch and promotes notch transactivation to augment ovarian cancer development.
    BMC Cancer. 2023;23:96.
    PubMed     Abstract available
    
    
    
20. ELSHARKAWI SM, Elkaffash D, Moez P, El-Etreby N, et al
    PCDH17 gene promoter methylation status in a cohort of Egyptian women with epithelial ovarian cancer.
    BMC Cancer. 2023;23:89.
    PubMed     Abstract available
    
    
    
21. WANG F, Yang Y, Du X, Zhu X, et al
    Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours.
    BMC Cancer. 2023;23:44.
    PubMed     Abstract available
    
    
    
22. ALWOSAIBAI K, Aalmri S, Mashhour M, Ghandorah S, et al
    PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers.
    BMC Cancer. 2023;23:13.
    PubMed     Abstract available
    
    
    December 2022
23. GAO W, Liu D, Sun H, Shao Z, et al
    SPP1 is a prognostic related biomarker and correlated with tumor-infiltrating immune cells in ovarian cancer.
    BMC Cancer. 2022;22:1367.
    PubMed     Abstract available
    
    
    
24. FANG F, Wang P, Huang H, Ye M, et al
    m(6)A RNA methylation regulator-based signature for prognostic prediction and its potential immunological role in uterine corpus endometrial carcinoma.
    BMC Cancer. 2022;22:1364.
    PubMed     Abstract available
    
    
    
25. YAO H, Li N, Yuan H
    Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations.
    BMC Cancer. 2022;22:1337.
    PubMed     Abstract available
    
    
    
26. NIE X, Liu D, Zheng M, Li X, et al
    HERPUD1 promotes ovarian cancer cell survival by sustaining autophagy and inhibit apoptosis via PI3K/AKT/mTOR and p38 MAPK signaling pathways.
    BMC Cancer. 2022;22:1338.
    PubMed     Abstract available
    
    
    
27. GUO X, Lin C, Zhao J, Tang M, et al
    Development of a novel predictive model for lymph node metastasis in patients with endometrial endometrioid carcinoma.
    BMC Cancer. 2022;22:1333.
    PubMed     Abstract available
    
    
    November 2022
28. LI S, Yang S, Hong Y
    Higher thymocyte selection-associated high mobility group box (TOX) expression predicts poor prognosis in patients with ovarian cancer.
    BMC Cancer. 2022;22:1216.
    PubMed     Abstract available
    
    
    
29. NING L, Lang J, Long B, Wu L, et al
    Diagnostic value of circN4BP2L2 in type I and type II epithelial ovarian cancer.
    BMC Cancer. 2022;22:1210.
    PubMed     Abstract available
    
    
    
30. KIM JH, Lee DE, Ha HI, Jung JY, et al
    Surgical outcomes of ureteral reconstruction during cytoreductive surgery for ovarian cancer: a retrospective cohort study.
    BMC Cancer. 2022;22:1163.
    PubMed     Abstract available
    
    
    
31. WU Q, Zhang N, Xie X
    The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients.
    BMC Cancer. 2022;22:1157.
    PubMed     Abstract available
    
    
    
32. YUBERO A, Barquin A, Estevez P, Pajares B, et al
    Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.
    BMC Cancer. 2022;22:1150.
    PubMed     Abstract available
    
    
    
33. LI Y, Chen L, Lv J, Chen X, et al
    Clinical application of artificial neural network (ANN) modeling to predict BRCA1/2 germline deleterious variants in Chinese bilateral primary breast cancer patients.
    BMC Cancer. 2022;22:1125.
    PubMed     Abstract available
    
    
    October 2022
34. LI S, Wang X, Sui X, Zhang X, et al
    Clinical characteristics and survival outcomes in patients with ovarian strumal carcinoid.
    BMC Cancer. 2022;22:1090.
    PubMed     Abstract available
    
    
    September 2022
35. CHEN YA, Lu CY, Cheng WF, Kuo KT, et al
    An experimental model for ovarian cancer: propagation of ovarian cancer initiating cells and generation of ovarian cancer organoids.
    BMC Cancer. 2022;22:967.
    PubMed     Abstract available
    
    
    
36. KIM SI, Lee HC, Yoon HK, Kim HS, et al
    Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma.
    BMC Cancer. 2022;22:965.
    PubMed     Abstract available
    
    
    August 2022
37. YIN J, Wen Y, Zeng J, Zhang Y, et al
    CDC50A might be a novel biomarker of epithelial ovarian cancer-initiating cells.
    BMC Cancer. 2022;22:903.
    PubMed     Abstract available
    
    
    
38. ZHANG Y, Wu H, Yu Z, Li L, et al
    Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
    BMC Cancer. 2022;22:842.
    PubMed     Abstract available
    
    
    July 2022
39. BRAICU EI, Krause CL, Torsten U, Mecke H, et al
    HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients.
    BMC Cancer. 2022;22:831.
    PubMed     Abstract available
    
    
    
40. FANG DD, Tao R, Wang G, Li Y, et al
    Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
    BMC Cancer. 2022;22:752.
    PubMed     Abstract available
    
    
    
41. KENNEDY F, Shearsmith L, Holmes M, Rogers Z, et al
    Electronic patient-reported monitoring of symptoms during follow-up of ovarian cancer patients: a feasibility study.
    BMC Cancer. 2022;22:726.
    PubMed     Abstract available
    
    
    June 2022
42. SOHN EJ
    PIK3R3, a regulatory subunit of PI3K, modulates ovarian cancer stem cells and ovarian cancer development and progression by integrative analysis.
    BMC Cancer. 2022;22:708.
    PubMed     Abstract available
    
    
    
43. LIM H, Bang SH, Kim Y, Cho SH, et al
    Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study.
    BMC Cancer. 2022;22:703.
    PubMed     Abstract available
    
    
    
44. BORDE J, Laitman Y, Blumcke B, Niederacher D, et al
    Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
    BMC Cancer. 2022;22:706.
    PubMed     Abstract available
    
    
    
45. GOU R, Zheng M, Hu Y, Gao L, et al
    Identification and clinical validation of NUSAP1 as a novel prognostic biomarker in ovarian cancer.
    BMC Cancer. 2022;22:690.
    PubMed     Abstract available
    
    
    
46. ZHU S, Bao H, Zhang MC, Liu H, et al
    KAZN as a diagnostic marker in ovarian cancer: a comprehensive analysis based on microarray, mRNA-sequencing, and methylation data.
    BMC Cancer. 2022;22:662.
    PubMed     Abstract available
    
    
    
47. SONG Y, Qu H
    Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
    BMC Cancer. 2022;22:633.
    PubMed     Abstract available
    
    
    
48. XU Q, Liu Y, Wang S, Wang J, et al
    Interfering with the expression of EEF1D gene enhances the sensitivity of ovarian cancer cells to cisplatin.
    BMC Cancer. 2022;22:628.
    PubMed     Abstract available
    
    
    
49. YART L, Bastida-Ruiz D, Allard M, Dietrich PY, et al
    Linking unfolded protein response to ovarian cancer cell fusion.
    BMC Cancer. 2022;22:622.
    PubMed     Abstract available
    
    
    May 2022
50. LEIBOWITZ BD, Dougherty BV, Bell JSK, Kapilivsky J, et al
    Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
    BMC Cancer. 2022;22:587.
    PubMed     Abstract available
    
    
    
51. WEN H, Feng Z, Ma Y, Liu R, et al
    Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
    BMC Cancer. 2022;22:550.
    PubMed     Abstract available
    
    
    
52. HU X, Zhang J, Cao Y
    Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study.
    BMC Cancer. 2022;22:544.
    PubMed     Abstract available
    
    
    
53. MCLAUGHLIN PMJ, Klar M, Zwimpfer TA, Dutilh G, et al
    Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.
    BMC Cancer. 2022;22:508.
    PubMed     Abstract available
    
    
    
54. GLASS EB, Hoover AA, Bullock KK, Madden MZ, et al
    Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer.
    BMC Cancer. 2022;22:497.
    PubMed     Abstract available
    
    
    April 2022
55. SATO S, Matsushita H, Shintani D, Kobayashi Y, et al
    Association between effector-type regulatory T cells and immune checkpoint expression on CD8(+) T cells in malignant ascites from epithelial ovarian cancer.
    BMC Cancer. 2022;22:437.
    PubMed     Abstract available
    
    
    
56. BOWERS RR, Andrade MF, Jones CM, White-Gilbertson S, et al
    Autophagy modulating therapeutics inhibit ovarian cancer colony generation by polyploid giant cancer cells (PGCCs).
    BMC Cancer. 2022;22:410.
    PubMed     Abstract available
    
    
    
57. AYYAGARI V, Li M, Pasman Z, Wang X, et al
    Assessment of the diagnostic and prognostic relevance of ACAT1 and CE levels in plasma, peritoneal fluid and tumor tissue of epithelial ovarian cancer patients - a pilot study.
    BMC Cancer. 2022;22:387.
    PubMed     Abstract available
    
    
    
58. WALTHER F, Berther JL, Lalos A, Ramser M, et al
    High ratio of pCXCR4/CXCR4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy.
    BMC Cancer. 2022;22:376.
    PubMed     Abstract available
    
    
    
59. KONO-SATO T, Miyai K, Yamagishi Y, Miyamoto M, et al
    Intraepithelial lymphocytes are indicators of better prognosis in surgically resected endometrioid-type endometrial carcinomas at early and advanced stages.
    BMC Cancer. 2022;22:361.
    PubMed     Abstract available
    
    
    March 2022
60. SUH YJ, Lee B, Kim K, Jeong Y, et al
    Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
    BMC Cancer. 2022;22:346.
    PubMed     Abstract available
    
    
    
61. XIAOHUA ZHU, Xie Y, Huang W, Chen Z, et al
    NAP1L1 promotes tumor proliferation through HDGF/C-JUN signaling in ovarian cancer.
    BMC Cancer. 2022;22:339.
    PubMed     Abstract available
    
    
    
62. WANG W, Wang T, Liu Z, He J, et al
    Overview of adjuvant radiotherapy on survival, failure pattern and toxicity in stage I to II endometrial carcinoma: a long-term multi-institutional analysis in China.
    BMC Cancer. 2022;22:266.
    PubMed     Abstract available
    
    
    
63. BINDER PS, Hashim YM, Cripe J, Buchanan T, et al
    The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer.
    BMC Cancer. 2022;22:263.
    PubMed     Abstract available
    
    
    
64. SONG Z, Wang Y, Zhou Y, Zhang D, et al
    Nomograms to predict the prognosis in malignant ovarian germ cell tumors: a large cohort study.
    BMC Cancer. 2022;22:257.
    PubMed     Abstract available
    
    
    February 2022
65. ELBIAD O, Laraqui A, El Boukhrissi F, Mounjid C, et al
    Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
    BMC Cancer. 2022;22:208.
    PubMed     Abstract available
    
    
    
66. SUMINOKURA J, Miyamoto M, Yoshikawa T, Kouta H, et al
    Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis.
    BMC Cancer. 2022;22:176.
    PubMed     Abstract available
    
    
    
67. SHARMA AL, Meitei PM, Machathoibi TC, Singh NT, et al
    Ovarian cancer G protein-coupled receptor 1 inhibits A549 cells migration through casein kinase 2alpha intronless gene and neutral endopeptidase.
    BMC Cancer. 2022;22:143.
    PubMed     Abstract available
    
    
    January 2022
68. LI B, Lou G, Zhang J, Cao N, et al
    Repression of lncRNA PART1 attenuates ovarian cancer cell viability, migration and invasion through the miR-503-5p/FOXK1 axis.
    BMC Cancer. 2022;22:124.
    PubMed     Abstract available
    
    
    
69. WONG-BROWN MW, van der Westhuizen A, Bowden NA
    Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.
    BMC Cancer. 2022;22:100.
    PubMed     Abstract available
    
    
    
70. CHEN W, Shan B, Zhou S, Yang H, et al
    Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.
    BMC Cancer. 2022;22:92.
    PubMed     Abstract available
    
    
    
71. LI Y, Gong X, Hu T, Chen Y, et al
    Two novel prognostic models for ovarian cancer respectively based on ferroptosis and necroptosis.
    BMC Cancer. 2022;22:74.
    PubMed     Abstract available
    
    
    
72. SATO M, Sato S, Shintani D, Hanaoka M, et al
    Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma.
    BMC Cancer. 2022;22:59.
    PubMed     Abstract available
    
    
    
73. PARK SJ, Chang SJ, Suh DH, Kong TW, et al
    A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer.
    BMC Cancer. 2022;22:28.
    PubMed     Abstract available
    
    
    
74. AGHA N, Alshamsan B, Al-Farsi S, Ateya HA, et al
    Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women.
    BMC Cancer. 2022;22:18.
    PubMed     Abstract available
    
    
    
75. NING L, Lang J, Wu L
    Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer.
    BMC Cancer. 2022;22:6.
    PubMed     Abstract available
    
    
    
76. LAI Z, Brosnan M, Sokol ES, Xie M, et al
    Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
    BMC Cancer. 2022;22:13.
    PubMed     Abstract available
    
    
    December 2021
77. AZRIBI F, Abdou E, Dawoud E, Ashour M, et al
    Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
    BMC Cancer. 2021;21:1350.
    PubMed     Abstract available
    
    
    October 2021
78. CREEDEN JF, Nanavaty NS, Einloth KR, Gillman CE, et al
    Homologous recombination proficiency in ovarian and breast cancer patients.
    BMC Cancer. 2021;21:1154.
    PubMed     Abstract available
    
    
    
79. GERNIER F, Ahmed-Lecheheb D, Pautier P, Floquet A, et al
    "Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovaria
    BMC Cancer. 2021;21:1147.
    PubMed     Abstract available
    
    
    
80. HU X, Li D, Liang Z, Liao Y, et al
    Indirect comparison of the diagnostic performance of (18)F-FDG PET/CT and MRI in differentiating benign and malignant ovarian or adnexal tumors: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:1080.
    PubMed     Abstract available
    
    
    September 2021
81. HASENBURG A, Eichkorn D, Vosshagen F, Obermayr E, et al
    Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial.
    BMC Cancer. 2021;21:1037.
    PubMed     Abstract available
    
    
    
82. QIAO ZW, Jiang Y, Wang L, Wang L, et al
    LINC00852 promotes the proliferation and invasion of ovarian cancer cells by competitively binding with miR-140-3p to regulate AGTR1 expression.
    BMC Cancer. 2021;21:1004.
    PubMed     Abstract available
    
    
    
83. AMAYA C, Luo S, Baigorri J, Baucells R, et al
    Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells.
    BMC Cancer. 2021;21:981.
    PubMed     Abstract available
    
    
    August 2021
84. SU R, Jin C, Zhou L, Cao Y, et al
    Construction of a ceRNA network of hub genes affecting immune infiltration in ovarian cancer identified by WGCNA.
    BMC Cancer. 2021;21:970.
    PubMed     Abstract available
    
    
    July 2021
85. WANG H, Fu Y
    NR1D1 suppressed the growth of ovarian cancer by abrogating the JAK/STAT3 signaling pathway.
    BMC Cancer. 2021;21:871.
    PubMed     Abstract available
    
    
    
86. YAN X, Zhang S, Jia J, Yang J, et al
    Exploring the malnutrition status and impact of total parenteral nutrition on the outcome of patients with advanced stage ovarian cancer.
    BMC Cancer. 2021;21:799.
    PubMed     Abstract available
    
    
    
87. WANG W, Zou L, Wang T, Liu Z, et al
    Treatment optimization of pelvic external beam radiation and/or vaginal brachytherapy for patients with stage I to II high-risk Endometrioid adenocarcinoma: a retrospective multi-institutional analysis.
    BMC Cancer. 2021;21:774.
    PubMed     Abstract available
    
    
    
88. LI Y, Jaiswal SK, Kaur R, Alsaadi D, et al
    Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer.
    BMC Cancer. 2021;21:768.
    PubMed     Abstract available
    
    
    June 2021
89. HE X, Wei L, Li R, Jing S, et al
    Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study.
    BMC Cancer. 2021;21:738.
    PubMed     Abstract available
    
    
    
90. REID BM, Vyas S, Chen Z, Chen A, et al
    Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
    BMC Cancer. 2021;21:714.
    PubMed     Abstract available
    
    
    
91. KOTNIK U, Peterlin B, Lovrecic L
    Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines.
    BMC Cancer. 2021;21:665.
    PubMed     Abstract available
    
    
    May 2021
92. HAWARDEN A, Russell B, Gee ME, Kayali F, et al
    Correction to: Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study.
    BMC Cancer. 2021;21:614.
    PubMed    
    
    
    
93. WANG B, Wang S, Ren W
    Development and validation of a nomogram to predict survival outcome among epithelial ovarian cancer patients with site-distant metastases: a population-based study.
    BMC Cancer. 2021;21:609.
    PubMed     Abstract available
    
    
    
94. PIROLLI R, de Alencar VTL, Estati FL, Ribeiro ARG, et al
    Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort.
    BMC Cancer. 2021;21:525.
    PubMed     Abstract available
    
    
    
95. LAPKE N, Chen CH, Chang TC, Chao A, et al
    Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
    BMC Cancer. 2021;21:499.
    PubMed     Abstract available
    
    
    
96. WANG C, Hu K, Deng L, He W, et al
    Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy.
    BMC Cancer. 2021;21:491.
    PubMed     Abstract available
    
    
    
97. SHIN W, Park SY, Kang S, Lim MC, et al
    How to manage synchronous endometrial and ovarian cancer patients?
    BMC Cancer. 2021;21:489.
    PubMed     Abstract available
    
    
    April 2021
98. LEANDERSSON P, Hogberg T, Dickman PW, Malander S, et al
    Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal/pelvic cancers in Sweden 1960-2014: A population-based cohort study.
    BMC Cancer. 2021;21:465.
    PubMed     Abstract available
    
    
    
99. XUE B, Li S, Jin X, Liu L, et al
    Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.
    BMC Cancer. 2021;21:452.
    PubMed     Abstract available
    
    
    
100. LI S, Yang T, Xiang Y, Li X, et al
     Clinical characteristics and survival outcomes of malignant struma ovarii confined to the ovary.
     BMC Cancer. 2021;21:383.
     PubMed     Abstract available
     
     
     
101. HAWARDEN A, Russell B, Gee ME, Skayali F, et al
     Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study.
     BMC Cancer. 2021;21:378.
     PubMed     Abstract available
     
     
     March 2021
102. ZHU C, Zhu J, Qian L, Liu H, et al
     Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
     BMC Cancer. 2021;21:322.
     PubMed     Abstract available
     
     
     
103. TOPNO R, Singh I, Kumar M, Agarwal P, et al
     Integrated bioinformatic analysis identifies UBE2Q1 as a potential prognostic marker for high grade serous ovarian cancer.
     BMC Cancer. 2021;21:220.
     PubMed     Abstract available
     
     
     February 2021
104. GUO J, Satoh K, Tabata S, Mori M, et al
     Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells.
     BMC Cancer. 2021;21:174.
     PubMed     Abstract available
     
     
     
105. ZHANG H, Zhang K, Xu Z, Chen Z, et al
     MicroRNA-545 suppresses progression of ovarian cancer through mediating PLK1 expression by a direct binding and an indirect regulation involving KDM4B-mediated demethylation.
     BMC Cancer. 2021;21:163.
     PubMed     Abstract available
     
     
     January 2021
106. LI J, Yue H, Yu H, Lu X, et al
     Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer.
     BMC Cancer. 2021;21:67.
     PubMed     Abstract available
     
     
     
107. YAN S, Fang J, Chen Y, Xie Y, et al
     Correction to: Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer.
     BMC Cancer. 2021;21:55.
     PubMed    
     
     
     
108. GRIMES MM, Kenney SR, Dominguez DR, Brayer KJ, et al
     The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo.
     BMC Cancer. 2021;21:40.
     PubMed     Abstract available
     
     
     
109. KAYAHASHI K, Mizumoto Y, Matsuoka A, Obata T, et al
     Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
     BMC Cancer. 2021;21:32.
     PubMed     Abstract available
     
     
     December 2020
110. KIM SI, Hwang WY, Lee M, Kim HS, et al
     Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles.
     BMC Cancer. 2020;20:1199.
     PubMed     Abstract available
     
     
     
111. YAN S, Fang J, Chen Y, Xie Y, et al
     Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer.
     BMC Cancer. 2020;20:1205.
     PubMed     Abstract available
     
     
     November 2020
112. TSUTSUMI M, Miura H, Inagaki H, Shinkai Y, et al
     An aggressive systemic mastocytosis preceded by ovarian dysgerminoma.
     BMC Cancer. 2020;20:1162.
     PubMed     Abstract available
     
     
     October 2020
113. LI M, Cheng X, Rong R, Gao Y, et al
     High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
     BMC Cancer. 2020;20:1032.
     PubMed     Abstract available
     
     
     
114. SONG L, Tang Z, Peng C, Yang Y, et al
     Cell type-specific genotoxicity in estrogen-exposed ovarian and fallopian epithelium.
     BMC Cancer. 2020;20:1020.
     PubMed     Abstract available
     
     
     
115. JOHANSEN G, Dahm-Kahler P, Staf C, Floter Radestad A, et al
     A Swedish Nationwide prospective study of oncological and reproductive outcome following fertility-sparing surgery for treatment of early stage epithelial ovarian cancer in young women.
     BMC Cancer. 2020;20:1009.
     PubMed     Abstract available
     
     
     
116. FOGG KC, Miller AE, Li Y, Flanigan W, et al
     Ovarian cancer cells direct monocyte differentiation through a non-canonical pathway.
     BMC Cancer. 2020;20:1008.
     PubMed     Abstract available
     
     
     
117. STOCKLEY J, Akhand R, Kennedy A, Nyberg C, et al
     Detection of MCM5 as a novel non-invasive aid for the diagnosis of endometrial and ovarian tumours.
     BMC Cancer. 2020;20:1000.
     PubMed     Abstract available
     
     
     
118. HOOVER AA, Hufnagel DH, Harris W, Bullock K, et al
     Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer.
     BMC Cancer. 2020;20:970.
     PubMed     Abstract available
     
     
     
119. ESCALONA RM, Bilandzic M, Western P, Kadife E, et al
     TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
     BMC Cancer. 2020;20:960.
     PubMed     Abstract available
     
     
     September 2020
120. HU J, Jiao X, Zhu L, Guo H, et al
     Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma.
     BMC Cancer. 2020;20:938.
     PubMed     Abstract available
     
     
     
121. ZHANG D, Chen X, Xia H, Wang L, et al
     Promotion of the occurrence of endometrioid carcinoma by S100 calcium binding protein P.
     BMC Cancer. 2020;20:845.
     PubMed     Abstract available
     
     
     August 2020
122. LI N, Gou J, Li L, Ming X, et al
     Staging procedures fail to benefit women with borderline ovarian tumours who want to preserve fertility: a retrospective analysis of 448 cases.
     BMC Cancer. 2020;20:769.
     PubMed     Abstract available
     
     
     June 2020
123. ITO M, Kodaira T, Koide Y, Okuda T, et al
     Role of high-dose salvage radiotherapy for oligometastases of the localised abdominal/pelvic lymph nodes: a retrospective study.
     BMC Cancer. 2020;20:540.
     PubMed     Abstract available
     
     
     May 2020
124. VAN DER MERWE NC, Oosthuizen J, Theron M, Chong G, et al
     The contribution of large genomic rearrangements in BRCA1 and BRCA2 to South African familial breast cancer.
     BMC Cancer. 2020;20:391.
     PubMed     Abstract available
     
     
     
125. PARK SJ, Shim SH, Ji YI, Kwon SH, et al
     Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial.
     BMC Cancer. 2020;20:385.
     PubMed     Abstract available
     
     
     April 2020
126. TANABE Y, Shiraishi S, Hashimoto K, Ikeda K, et al
     Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
     BMC Cancer. 2020;20:325.
     PubMed     Abstract available
     
     
     March 2020
127. PRZYBYTKOWSKI E, Davis T, Hosny A, Eismann J, et al
     An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
     BMC Cancer. 2020;20:197.
     PubMed     Abstract available
     
     
     
128. ONWUKA JU, Okekunle AP, Olutola OM, Akpa OM, et al
     Lipid profile and risk of ovarian tumours: a meta-analysis.
     BMC Cancer. 2020;20:200.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: